BACKGROUND: Sustained release of local anesthetics is frequently associated with myotoxicity. The authors investigated the role of particulate delivery systems and of the pattern of drug release in causing myotoxicity. METHODS: Rats were given sciatic nerve blocks with bupivacaine solutions, two types of bupivacaine-containing microparticles (polymeric microspheres and lipid-protein-sugar particles), or blank particles with or without bupivacaine in the carrier fluid. Myotoxicity was scored in histologic sections of the injection sites. Bupivacaine release kinetics from the particles were measured. Myotoxicity of a range of bupivacaine concentrations from exposures up to 3 weeks was assessed in C2C12 myotubes, with or without microparticles. RESULTS: Both types of bupivacaine-loaded microparticles, but not blank particles, were associated with myotoxicity. Whereas 0.5% bupivacaine solution caused little myotoxicity, a concentration of bupivacaine that mimicked the amount of bupivacaine released initially from particles caused myotoxicity. Local anesthetics showed both concentration and time-dependent myotoxicity in C2C12s. Importantly, even very low concentrations that were nontoxic over brief exposures became highly toxic after days or weeks of exposure. The presence of particles did not increase bupivacaine myotoxicity in vitro but did in vivo. Findings applied to both particle types. CONCLUSIONS: Whereas the release vehicles themselves were not myotoxic, both burst and extended release of bupivacaine were. A possible implication of the latter finding is that myotoxicity is an inevitable concomitant of sustained release of local anesthetics. Particles, and perhaps other vehicles, may enhance local toxicity through indirect mechanisms.
BACKGROUND: Sustained release of local anesthetics is frequently associated with myotoxicity. The authors investigated the role of particulate delivery systems and of the pattern of drug release in causing myotoxicity. METHODS:Rats were given sciatic nerve blocks with bupivacaine solutions, two types of bupivacaine-containing microparticles (polymeric microspheres and lipid-protein-sugar particles), or blank particles with or without bupivacaine in the carrier fluid. Myotoxicity was scored in histologic sections of the injection sites. Bupivacaine release kinetics from the particles were measured. Myotoxicity of a range of bupivacaine concentrations from exposures up to 3 weeks was assessed in C2C12 myotubes, with or without microparticles. RESULTS: Both types of bupivacaine-loaded microparticles, but not blank particles, were associated with myotoxicity. Whereas 0.5% bupivacaine solution caused little myotoxicity, a concentration of bupivacaine that mimicked the amount of bupivacaine released initially from particles caused myotoxicity. Local anesthetics showed both concentration and time-dependent myotoxicity in C2C12s. Importantly, even very low concentrations that were nontoxic over brief exposures became highly toxic after days or weeks of exposure. The presence of particles did not increase bupivacainemyotoxicity in vitro but did in vivo. Findings applied to both particle types. CONCLUSIONS: Whereas the release vehicles themselves were not myotoxic, both burst and extended release of bupivacaine were. A possible implication of the latter finding is that myotoxicity is an inevitable concomitant of sustained release of local anesthetics. Particles, and perhaps other vehicles, may enhance local toxicity through indirect mechanisms.
Authors: Daniel S Kohane; Nikolaus Plesnila; Sunu S Thomas; Dean Le; Robert Langer; Michael A Moskowitz Journal: Brain Res Date: 2002-08-16 Impact factor: 3.252
Authors: Daniel S Kohane; Michael Lipp; Ramsey C Kinney; Douglas C Anthony; David N Louis; Noah Lotan; Robert Langer Journal: J Biomed Mater Res Date: 2002-03-05
Authors: Daniel S Kohane; Sarah E Smith; David N Louis; Gaia Colombo; Peter Ghoroghchian; Nicole G M Hunfeld; Charles B Berde; Robert Langer Journal: Pain Date: 2003-07 Impact factor: 6.961
Authors: Nicole A Friel; Vincent M Wang; Mark A Slabaugh; FanChia Wang; Susan Chubinskaya; Brian J Cole Journal: J Shoulder Elbow Surg Date: 2012-07-20 Impact factor: 3.019
Authors: Todd Hoare; Daryl Sivakumaran; Cristina F Stefanescu; Michael W Lawlor; Daniel S Kohane Journal: Acta Biomater Date: 2011-12-29 Impact factor: 8.947
Authors: Iris Shichor; Noam Shomron; Michael W Lawlor; Seul A Bae; Janet Zoldan; Robert Langer; Daniel S Kohane Journal: Biomaterials Date: 2012-02-16 Impact factor: 12.479
Authors: J Brian McAlvin; Robert F Padera; Sahadev A Shankarappa; Gally Reznor; Albert H Kwon; Homer H Chiang; Jason Yang; Daniel S Kohane Journal: Biomaterials Date: 2014-03-06 Impact factor: 12.479
Authors: Sahadev A Shankarappa; Jonathan H Tsui; Kristine N Kim; Gally Reznor; Jenny C Dohlman; Robert Langer; Daniel S Kohane Journal: Proc Natl Acad Sci U S A Date: 2012-10-08 Impact factor: 11.205
Authors: Hila Epstein-Barash; Iris Shichor; Albert H Kwon; Sherwood Hall; Michael W Lawlor; Robert Langer; Daniel S Kohane Journal: Proc Natl Acad Sci U S A Date: 2009-04-13 Impact factor: 11.205
Authors: J Brian McAlvin; Gally Reznor; Sahadev A Shankarappa; Cristina F Stefanescu; Daniel S Kohane Journal: Anesth Analg Date: 2013-03-04 Impact factor: 5.108